IGF-1 LR3: the long-acting IGF-1 analog

IGF-1 LR3 is a recombinant analog of human IGF-1 that contains a 13-amino-acid N-terminal extension and a single point substitution (glutamate-3 to arginine-3) that together dramatically reduce binding to IGF-binding proteins (IGFBPs). this greatly extends its effective half-life and increases the fraction of bioactive free IGF-1 available to bind the IGF-1 receptor. it is used as a research reagent and a community performance peptide, but it is not approved for human use by any regulatory agency.

what is IGF-1 LR3?

IGF-1 LR3 is a 83-amino-acid modified version of native IGF-1 that was developed originally as a research tool to enable sustained IGF-1 receptor stimulation in cell culture without the confounding rapid degradation of native IGF-1. its structural differences from native IGF-1 are specific and consequential.

native human IGF-1 is a 70-amino-acid single-chain polypeptide that circulates almost entirely (more than 98 percent) bound to a family of six IGF-binding proteins (IGFBP-1 through IGFBP-6). the IGFBPs function as both a reservoir (extending IGF-1's circulating half-life from a few minutes to hours) and as a modulator (limiting how much bioactive free IGF-1 reaches the receptor at any moment). when researchers want to study IGF-1 receptor signaling in isolation, the IGFBP buffering system is a complication, because exogenously added IGF-1 is rapidly sequestered.

IGF-1 LR3 solves that problem by two structural modifications: a 13-residue N-terminal extension derived from the signal sequence of IGF-1, and the substitution of glutamate at position 3 with arginine (hence "R3"). the N-terminal extension and the R3 substitution together reduce IGFBP binding affinity by roughly 2 to 3 orders of magnitude. the result is a version of IGF-1 that circulates largely free, with an effective half-life of approximately 20 to 30 hours compared to roughly 15 minutes for free native IGF-1. IGF-1 LR3 still binds the IGF-1 receptor (IGF-1R) with slightly reduced affinity relative to native IGF-1, but this is more than compensated by its extended availability [1].

how does IGF-1 signal at the receptor?

IGF-1 activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, which triggers two major downstream cascades: PI3K-Akt-mTOR (driving protein synthesis and cell survival) and MAPK/ERK (driving cell proliferation). these pathways are well characterized and underlie IGF-1's roles in growth, muscle hypertrophy, and metabolism.

the IGF-1 receptor is structurally similar to the insulin receptor and the two receptors share overlapping but distinct signaling consequences. when IGF-1 (or IGF-1 LR3) binds IGF-1R, the receptor undergoes autophosphorylation and activates insulin receptor substrate proteins (IRS-1/IRS-2), which in turn activate PI3K, generating PIP3. PIP3 activates Akt, and activated Akt phosphorylates mTORC1, the master regulator of protein synthesis. the parallel MAPK pathway drives gene transcription changes relevant to proliferation. in skeletal muscle, these signals promote hypertrophy by increasing translational efficiency and activating satellite cells (muscle stem cells) [2].

the insulin-like activity of IGF-1 at the insulin receptor is real but lower than at IGF-1R. at supraphysiologic concentrations, however, IGF-1 and IGF-1 LR3 can stimulate meaningful insulin-receptor signaling, which is the basis for the hypoglycemia risk that is considered a primary safety concern for any exogenous IGF-1 analog.

Philippou and Barton reviewed strategies for optimizing IGF-1 for skeletal muscle therapeutics in 2014, providing a framework for understanding where analogs like LR3 fit in the broader effort to harness IGF-1 signaling therapeutically without the limitations of native IGF-1 [3].

what does the evidence show?

the evidence for IGF-1 LR3 in humans is extremely limited. it is primarily known as a research reagent used in cell biology and as a preclinical pharmacology tool. no controlled human clinical trials of IGF-1 LR3 have been published. the body of evidence for IGF-1 itself in human disease (IGF-1 deficiency, cachexia, growth failure) is more developed but still restricted in scope.

in cell biology, IGF-1 LR3 is used to saturate IGF-1 receptors without the IGFBP buffering that complicates interpretation of native IGF-1 experiments. it appears in thousands of basic science publications as a reagent, not as a therapeutic agent under study. this is an important distinction: publication frequency for IGF-1 LR3 in PubMed reflects its utility as a laboratory tool, not a clinical evidence base.

the only FDA-approved product related to IGF-1 is mecasermin (Increlex), which is recombinant native IGF-1 (not LR3) approved for the treatment of growth failure in children with severe primary IGF-1 deficiency. the approval program for mecasermin used recombinant native IGF-1, not the LR3 analog, and the two compounds have different pharmacokinetic profiles. IGF-1 LR3 has never been in a Phase 1, Phase 2, or Phase 3 human trial as a therapeutic agent.

the academic literature on IGF-1 in skeletal muscle therapeutics acknowledges the challenge that has prevented IGF-1 analogs from becoming approved drugs: supraphysiologic IGF-1 signaling is robustly pro-anabolic but also potentially pro-mitogenic, meaning it may promote cell proliferation in contexts where that is undesirable, including in pre-existing tumors. Philippou and Barton's 2014 review summarizes the balance of therapeutic opportunity and risk that makes IGF-1-based therapeutics difficult to advance [3].

regulatory status and safety

IGF-1 LR3 is not approved for human use by any regulatory agency. it is not a licensed pharmaceutical in any country. the primary theoretical safety concerns are hypoglycemia from insulin-like signaling, promotion of tumor growth in susceptible individuals, and the absence of any human safety database.

because IGF-1 LR3 has never been in human clinical trials, there is no systematic human safety dataset. the safety concerns are extrapolated from what is known about native IGF-1 and from the preclinical pharmacology of LR3 itself. the extended half-life that makes LR3 pharmacologically interesting also means that any adverse effects would persist substantially longer than with native IGF-1. hypoglycemia is the most acutely concerning risk: IGF-1 at sufficient concentrations lowers blood glucose via insulin-receptor cross-signaling, and the free-bioavailable fraction of LR3 is by design much higher than for native IGF-1.

IGF-1 LR3 is on the WADA prohibited list under S2.4 (insulins and their analogs, and also under the growth-factor category) and is banned in all competitive sport.

where it fits in the peptide landscape

IGF-1 LR3 sits downstream of the GH-IGF-1 axis. peptides like tesamorelin and ipamorelin raise IGF-1 indirectly by stimulating pituitary GH release; IGF-1 LR3 bypasses that entire upstream axis and delivers IGF-1-level signaling directly at the receptor. this makes it pharmacologically distinct but also further removed from any physiologic feedback control.

the mechanistic relatives on Peptides Academy include tesamorelin, which raises IGF-1 indirectly via GHRH receptor stimulation and pituitary GH amplification, and ipamorelin, which raises GH via the ghrelin receptor. both act on upstream nodes in the GH-IGF-1 axis and preserve some degree of physiologic feedback regulation. IGF-1 LR3 acts downstream of all of that regulation, directly at the tissue level. mechanically related growth factors studied for muscle applications include MGF (mechano growth factor), an IGF-1 splice variant that is activated by mechanical loading and has a distinct receptor-interaction profile. for the broader anabolic peptide context, see our muscle-building peptides guide.